<DOC>
	<DOC>NCT01658839</DOC>
	<brief_summary>The purpose of this study was to assess the safety and describe the steady-state plasma pharmacokinetic (PK) profiles of Travoprost ophthalmic solution, 0.004% (new formulation) following a once daily administration for 7 days in pediatric glaucoma or ocular hypertension patients.</brief_summary>
	<brief_title>Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Diagnosis of glaucoma or ocular hypertension in at least 1 eye. Parent/legal guardian must provide informed consent, and children must agree to sign an approved assent form when applicable. Must agree to comply with the requirements of the study and must be accompanied by a parent/guardian. Other protocoldefined inclusion criteria may apply. Females of childbearing potential that are currently pregnant, have a positive result on a pregnancy test at the Screening Visit, intend to become pregnant during the study period, are breast feeding, or are not using birth control measures. One sighted eye or monocular, including patients who cannot be dosed in both eyes for any reason. History of chronic, recurrent or severe inflammatory eye disease. Ocular trauma requiring medical attention within the past 3 months prior to the Screening Visit. Ocular infection or ocular inflammation within the past 30 days prior to the Screening Visit. Clinically significant or progressive retinal disease such as retinal degeneration, diabetic retinopathy, or retinal detachment. Other severe ocular pathology (including severe dry eye), that in the opinion of the Investigator, would preclude the administration of a topical prostaglandin analogue. Intraocular surgery within the past 30 days prior to the Screening Visit. Any abnormality preventing reliable tonometry. Any other conditions including severe illness which would make the patient, in the opinion of the Investigator, unsuitable for the study. Hypersensitivity to prostaglandin analogues or to any component of the study medications in the opinion of the Investigator. Therapy with another investigational agent or device within 30 days prior to the Screening Visit. Body weight &lt; 5kg. Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>pediatric glaucoma</keyword>
	<keyword>pediatric ocular hypertension</keyword>
	<keyword>travoprost</keyword>
</DOC>